◈ Nootpedia
Compact view
Research pass: thorough Pharmaceutical · Oral STRONG-CANDIDATE MEDIUM

Selegiline

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict STRONG-CANDIDATE MEDIUM

Verdict applies to LOW ORAL (1-2.5 mg) tier only — strong mechanistic + animal-longevity case + clean human safety at this dose, but direct healthy-young-adult cognitive evidence is thin. Emsam tiers separately verdicted in body. Would upgrade to PRIMARY-PICK if 23andMe shows DRD2 Taq1A A1 carrier or low-DA-tone genotype where preservation matters more; would downgrade to OPTIONAL-ADD if baseline mood + drive already strong without it.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    —

    - Tier 1 (1-2.5 mg oral): STRONG-CANDIDATE. Add post-baseline (June 2026 bloodwork + 23andMe) AFTER bromantane + modafinil are established and steady-state. Pairs cleanly with V5 stack. Daily-safe, no diet constraint, $25/mo. The "brain insurance" argument tracks with brain-priority + MMA subconcussive impact context. - Tier 2 (Emsam 6 mg): OPTIONAL-ADD, lean WATCH-LIST. No clear marginal benefit over oral microdose at age 20 absent diagnosable depression. Cost + skin irritation + Rx friction don't pencil out vs the $25/mo oral path. Reconsider only if: (a) baseline reveals depression/dysthymia, (b) low-oral tier underwhelms after 8 weeks AND mood is the limiting factor. - Tier 3 (Emsam 9-12 mg): WATCH-LIST. Tyramine constraint at age 20 with active social/restaurant life is too costly without a treatment-resistant depression diagnosis. Not a fit.

  • 30-50, executive maintenance
    —

    - Tier 1: STRONG-CANDIDATE — DA preservation insurance starts to matter as MAO-B activity rises with age. - Tier 2: OPTIONAL-ADD if mood/drive are limiting factors. - Tier 3: SKIP unless treatment-resistant depression.

  • 50+, mild cognitive decline
    —

    - Tier 1: STRONG-CANDIDATE — best-evidence dose tier in this demographic. Real DA preservation argument. - Tier 2: STRONG-CANDIDATE if mood comorbidity. - Tier 3: PHYSICIAN-DIRECTED only.

  • Anxiety-prone
    C

    at all tiers. Selegiline can mildly increase NE — anxiety amplification possible. Start at 1 mg or even every-other-day at low tier and titrate.

  • High athletic load, tested status
    S

    is NOT WADA-banned. Not on the prohibited list. Untested status (Dylan) makes this moot anyway. L-amphetamine metabolite at oral doses can theoretically trigger amphetamine urine screen false positives — flag for any drug-tested context.

  • Sleep-disordered
    U

    AM dosing only. NOT suitable PM. Some users report vivid dreams.

  • Recovery-focused (post-injury, post-illness)
    B-

    mechanism for stroke/TBI recovery (open-label data). Not first-line. BPC-157, GHK-Cu, methylene blue have stronger recovery cases.

  • Strength/anabolic-focused
    N

    — not anabolic, not catabolic, not in the muscle-building pathway. Mild libido enhancement reported.

▸ Subjective experience (deep)

Low oral (1-2.5 mg/day)

"Subtle to imperceptible" is the modal report. Some users report mild mood-lift, slightly enhanced drive/libido, less afternoon flatness — typically over 2-6 weeks of daily use, not acute. No "you can feel it kicking in" character. Doesn't feel like a stimulant. Tolerable for most. Insomnia risk is real but mostly avoided by AM-only dosing.

Emsam 6 mg/24hr patch

Onset over 1-3 weeks. Reports: gradual mood lift, increased motivation/drive, reduced anhedonia, improved libido. Generally well-tolerated. The "always on" steady-state delivery (vs the daily-pulsed oral) feels different — less peaks, more sustained baseline shift. No dietary restriction at this tier. Common subjective: skin irritation at the patch site (15-25% in trials).

Emsam 9-12 mg/24hr patch

Reported as transformative by some users — the original external source claim "best thing ever" tracks at this tier. Stronger antidepressant effect, enhanced cognition by serotonin + dopamine + norepinephrine elevation simultaneously, MAOI-class mood lift. Caveat: the "slice of cheese could kill them" warning is also accurate at this tier. Users report constant low-grade dietary anxiety. Lifestyle constraint is significant — restaurants become a calculation, sauces become unknowable, accidentally eating an aged cheese gives you a window of fear before knowing if you'll get a hypertensive spike. NOT a dose tier you adopt casually.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Minimal at low oral dose. The standard nootropic-community framing is "no significant tolerance" and that's roughly accurate. Mechanism: MAO-B regenerates over ~40-day half-life, so steady-state inhibition is reached after ~6 weeks of daily dosing and stays there. Receptor downregulation is not a major tolerance mechanism here (see "no receptor downregulation" discussion in Mechanism section).
  • Recommended cycle: Daily indefinite at low oral. No cycling needed. Some users do 5-on / 2-off weekly to add tolerance insurance — not evidence-based but harmless.
  • Reset protocol: ~2-3 weeks washout if any reset desired. Full MAO-B regeneration takes ~6 weeks.

The "no receptor downregulation" claim — verification verdict

Mechanistically accurate at the low-oral tier. Selegiline's primary MoA (enzyme inhibition + TAAR1 weak agonism) does not produce the supraphysiologic synaptic flooding that drives D2 receptor downregulation in chronic amphetamine use. Animal data and the limited human DAT-imaging data (one PMC study) support this claim. The claim degrades at the 9-12 mg patch / >10 mg oral tier because L-amphetamine metabolite levels rise to clinically relevant amphetaminergic levels — but at those tiers tolerance/downregulation is the LEAST of your concerns vs the tyramine cliff.

▸ Stacking deep dive

Synergistic with

  • modafinil: Different mechanisms (DA-tone preservation via MAO-B vs DA reuptake inhibition + histamine + orexin). Stack is widely reported clean in the nootropic community. Modafinil + low-dose selegiline is in Dylan's V5 plan and the encyclopedia stacking section explicitly endorses this combination.
  • bromantane: Cleanly orthogonal — bromantane upregulates DA synthesis at the TH/AAAD level + raises brain GSH; selegiline preserves what's already there. No mechanism overlap, no shared liability.
  • l-tyrosine: PRN under cognitive stress. Tyrosine provides substrate, selegiline preserves the resulting DA. Synergistic within a stress-response window.
  • ALCAR: Mitochondrial support for DA neurons + selegiline's enzymatic preservation = compounding neuroprotection mechanisms. Mild synergy.
  • astaxanthin / DHA / NAC: Antioxidant/membrane support for the DA neurons selegiline is preserving. Generally additive.
  • bpap / ppap: These are next-gen TAAR1-selective enhancers without MAO inhibition. THEORETICALLY synergistic with selegiline at low dose (different mechanisms) but the rational move would be to choose ONE: if MAO-B inhibition is wanted, low-dose selegiline; if pure CAE without MAO inhibition is wanted, BPAP.

Avoid stacking with

  • bupropion (Wellbutrin): Increases dopaminergic activity (NDRI). Combined with MAO-B inhibitor not formally contraindicated at low selegiline dose, but introduces risk of hypertension + agitation. At 6+ mg patch it is contraindicated. Per Dylan's V5 plan, bupropion is an alternative-path choice — pick one or the other, not both.
  • SSRIs / SNRIs: Serotonin syndrome risk. At low-oral selegiline (1-2.5 mg) the risk is lower than at higher tiers — there are studies (PMC6019085) showing 4500+ PD patients on selegiline + antidepressant with only 11 cases serotonin syndrome and zero fatalities — but the FDA labels both Zelapar and Emsam as contraindicated with SSRIs.
  • MDMA, methamphetamine, cocaine, MAOIs (other), amphetamine high-dose: Catastrophic combinations.
  • other MAO-B or MAO-A inhibitors (rasagiline, phenelzine, tranylcypromine, isocarboxazid, linezolid, methylene blue): redundant + dangerous.
  • St. John's Wort / 5-HTP / L-tryptophan in high dose: serotonin syndrome risk at higher selegiline tiers. Note: Dylan's V5 plan includes L-tryptophan 1g pre-bed as a sleep adjunct. At 1-2.5 mg oral selegiline morning + L-tryptophan 1g night this should be fine (low tier + temporal separation + low dose tryptophan), but at any patch tier this would need re-evaluation.
  • adderall / vyvanse / dexedrine: at low oral selegiline risk is moderated; at any patch tier contraindicated.
  • DXM (dextromethorphan): contraindicated. Cough syrups containing DXM must be avoided. Use guaifenesin-only or codeine-only alternatives.
  • tramadol, meperidine (Demerol), methadone, fentanyl-class: contraindicated. Standard non-serotonergic opioids (morphine, oxycodone, hydromorphone) are generally OK but use caution.

Neutral / safe co-administration

  • Caffeine — no meaningful interaction at usual doses
  • Creatine — neutral
  • Citicoline / Alpha-GPC / DHA / PS — neutral, possibly mildly additive on cognition
  • Magnesium / Vitamin D / K2 / NAC — neutral
  • Selank / Semax / Adamax (Russian peptides) — no evidence of interaction; mechanistic distance suggests safe co-admin
  • Apigenin — some MAO-A inhibition theoretically, but at supplement doses not clinically meaningful with low-oral selegiline; cleaner with Emsam tiers if at all
  • Theanine, glycine, taurine, beta-alanine — neutral
▸ Drug interactions deep dive

Absolute contraindications (do not combine)

  • Other MAOIs: phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), rasagiline (Azilect), safinamide, linezolid (antibiotic), methylene blue (procedural use)
  • Meperidine (Demerol) — fatal interactions reported. Tell ER/anesthesiology.
  • Tramadol — same fatal interaction class.
  • Methadone — contraindicated.
  • Dextromethorphan (DXM) — psychosis + serotonin syndrome reports.
  • MDMA, methamphetamine — hypertensive crisis + serotonin syndrome.
  • Selective serotonin reuptake inhibitors (SSRIs): sertraline (Zoloft), fluoxetine (Prozac), paroxetine (Paxil), citalopram (Celexa), escitalopram (Lexapro), fluvoxamine — formally contraindicated per FDA label. Real-world data suggests citalopram + sertraline are the lower-risk SSRIs IF combination is unavoidable.
  • SNRIs: venlafaxine (Effexor), duloxetine (Cymbalta), desvenlafaxine — contraindicated.
  • TCAs: amitriptyline, clomipramine, imipramine — contraindicated.
  • Bupropion: package label contraindicated; clinical practice sometimes uses with caution at low selegiline dose, but DON'T combine.

Caution / monitor

  • Sympathomimetics (pseudoephedrine, ephedrine, phenylephrine OTC): risk of BP elevation. Avoid at high tiers; monitor at low oral.
  • CYP2B6 inducers (rifampin, efavirenz, carbamazepine, phenytoin): can lower selegiline + metabolite levels.
  • CYP2B6 inhibitors (clopidogrel, ticlopidine, voriconazole, sertraline at higher doses): can raise selegiline + metabolite levels.
  • Anesthetics: disclose to anesthesiologist. Some opioids (morphine, fentanyl) require modification of plan.

Tyramine — high-tier only

At 9-12 mg patch (and oral >10 mg) avoid:

  • Aged cheeses: cheddar, blue, parmesan, brie, camembert, gouda, gruyère
  • Aged/cured meats: salami, pepperoni, prosciutto, dry sausage, soppressata, salt-cured fish
  • Fermented soy: soy sauce (in quantity), miso, tofu (aged), tempeh
  • Fermented vegetables: sauerkraut, kimchi
  • Tap beer / draft beer / red wine (especially Chianti); bottled beer in moderation generally OK
  • Fava beans (broad beans)
  • Marmite, Vegemite
  • Overripe / spoiled food of any kind
  • Smoked fish

At 1-2.5 mg oral OR Emsam 6 mg patch: tyramine restrictions are NOT required. This is the central differentiator that makes the low-oral tier "daily-safe normal life" and makes the high-tier "lifestyle commitment."

▸ Pharmacogenomics

Primary CYP enzymes

  • CYP2B6 — primary metabolizer of selegiline. HIGHLY POLYMORPHIC. Common variants:
    • CYP2B6*6 (G516T + A785G) — reduced enzyme activity. Carriers (~25% of Europeans, ~50% of African ancestry) have higher selegiline parent + lower L-amph/L-meth metabolite levels at given dose. May tolerate higher dose with less amphetaminergic side effect.
    • CYP2B6*4 — increased activity. Faster metabolism, higher metabolite load, possibly more amphetaminergic side effects.
    • CYP2B6*5 — decreased activity.
  • CYP2C19 — secondary major contributor. Polymorphism status:
    • *CYP2C192, 3 (poor metabolizers)* — slower clearance.
    • CYP2C19*17 (ultrarapid) — faster clearance.
  • CYP3A4 — minor contributor.
  • CYP2D6 — NOT important for selegiline metabolism per multiple studies. The standard "CYP2D6 tells you everything about psych drugs" heuristic does NOT apply here.

Dopamine pathway polymorphisms (response prediction)

  • COMT Val158Met (rs4680): Met/Met homozygotes have lower COMT activity → naturally higher PFC DA tone. May respond to selegiline differently — possibly less marginal benefit (already DA-rich) and more side effects. Val/Val homozygotes (lower DA tone) may benefit more.
  • DRD2/ANKK1 Taq1A (rs1800497): A1 allele carriers have reduced D2 receptor density. May benefit more from DA-preserving compounds like selegiline. Worth checking on Dylan's 23andMe.
  • DRD4 7R repeat: novelty-seeking/impulsivity allele, hypothesized differential response — limited direct selegiline data.
  • MAOA-uVNTR (the "warrior gene"): affects MAO-A activity, not directly relevant to MAO-B-selective dose, but at 9-12 mg patch where MAO-A is also inhibited, low-activity MAOA carriers may experience disproportionate effect.

For Dylan specifically (23andMe results pending June 2026)

Flag these SNPs for review when results land:

  1. rs3745274 (CYP2B6*6 G516T): dose response prediction
  2. rs2279343 (CYP2B6*6 A785G): companion variant
  3. rs4244285 (CYP2C19*2): secondary metabolizer status
  4. rs12248560 (CYP2C19*17): ultrarapid metabolizer marker
  5. rs4680 (COMT Val158Met): baseline DA tone
  6. rs1800497 (DRD2/ANKK1 Taq1A): D2 receptor density baseline
  7. rs1799836 (MAOB intron 13): affects MAO-B baseline expression — possibly the most direct selegiline-relevant SNP. Some research suggests differential response to MAO-B inhibitors by MAOB genotype.

These SNPs are typically present on 23andMe v5 chip. Run them through Promethease / Genetic Lifehacks / the GENETICS-PHARMACOGENOMICS.md frame after results arrive.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
US Rx generic 5 mg capsules Local pharmacy w/ GoodRx coupon $20-30/mo for 30× 5 mg High Cheapest tier-1 path. Off-label nootropic Rx — telehealth psychiatry can write for fatigue/mild cognitive complaint or "early Parkinson's risk concern with family history." Cut into halves/quarters for 1-2.5 mg dosing.
US Rx Zydis ODT (Zelapar) 1.25 mg Local pharmacy ~$200-400/mo brand; generic ODT cheaper High Direct 1.25 mg dose without cutting. Better bioavailability + selectivity profile than cut tablets. Premium choice if affordable.
Indian pharmacy generic RxIndian / IndiaMart vendors $10-20/mo Medium-high Selegiline 5 mg widely available from same pharmacies as modafinil. Same vendor pool Dylan is already comfortable with for modafinil. COA recommended.
Veterinary selegiline US online vet pharmacy ~$15-30/mo Medium Sold for canine cognitive dysfunction syndrome (Anipryl). Same molecule, different label. Legally gray for human use. Skip unless Rx path closed.
US Rx Emsam 6/9/12 mg patch Specialty pharmacy $400-2799/mo brand; $20-80/mo with savings card / PAP High Generic NOT expected until 2035 (patent). Insurance coverage spotty. PAP/savings card is the realistic path.
Compounded transdermal selegiline US compounding pharmacies Variable, often $100-300/mo Variable Some compounding pharmacies make custom transdermal selegiline preparations. Not FDA-evaluated for tyramine bypass kinetics — assume tyramine restrictions might apply. Quality + COA verification critical.
Gray-market international Emsam International pharmacies $200-500/mo Low-medium Identity + COA risk. Not recommended given oral path is so cheap and effective at the nootropic tier.

For Dylan: clear recommendation = US Rx generic 5 mg capsules + pill cutter (already in V4 stack). $20-30/mo. Indian pharmacy is the backup if US Rx friction is high.

▸ Biomarkers to track (deep)

Baseline (before starting)

  • Resting BP + orthostatic BP delta (lying → standing) — establish baseline before MAO inhibition
  • HR resting
  • Mood self-report scale (PHQ-9 or simpler 0-10)
  • Sleep onset latency + total sleep time (Oura/ring data)
  • Libido / drive baseline (subjective)
  • Liver panel (ALT/AST)
  • 23andMe SNP review (CYP2B6, CYP2C19, COMT, DRD2, MAOB) — Dylan's pending June 2026

During use

  • Resting + orthostatic BP weekly first month, monthly thereafter
  • Mood + drive self-report weekly
  • Sleep metrics ongoing (Oura + subjective)
  • Patch site condition (Emsam tier only)
  • Watch for any tyramine-like symptoms even at low tier (headache, palpitations) — extremely unlikely but pattern-recognize

Post-cycle (if discontinuing)

  • 2-week observation for mood/drive baseline return
  • Continue tyramine awareness for 2 weeks (residual MAO inhibition)
  • Liver panel if symptomatic
▸ Controversies / open debates Live debate

Is selegiline actually neuroprotective in humans?

  • Knoll camp: YES — animal lifespan + DA neuron preservation + SOD/catalase upregulation translate to humans. DATATOP showed delay in PD progression.
  • Skeptic camp: NO — DATATOP's apparent neuroprotection is confounded by 40-day MAO-B half-life producing carryover symptomatic effect; long-term follow-up showed no actual disability postponement. American Academy of Neurology has concluded "insufficient evidence" for clinical neuroprotection.
  • My read: the in-vitro and animal mechanism is real (BDNF/GDNF upregulation, SOD activity, DA neuron preservation in ischemia/MPTP models). The human translation is plausible but not proven. For a 20yo with brain-priority and decades of compounding to gain, mechanism-level plausibility + low-cost / low-risk = reasonable bet. Don't sell this as "proven brain protection" — sell it as "highest-evidence available DA-preservation tool with manageable risk profile."

"No receptor downregulation" — true?

Verified above (Mechanism section). True at the low-oral tier; degrades at higher tiers due to L-amphetamine metabolite contribution. The external source's emphasis on this is correct and is a legitimate mechanistic differentiator from amphetamine-class stimulants.

Why not just use BPAP / PPAP?

BPAP/PPAP are next-generation CAE compounds Knoll developed AFTER deprenyl. They lack MAO inhibition entirely and act purely as TAAR1-mediated impulse-coupled DA enhancers. Theoretically cleaner. Practical issue: BPAP/PPAP are research chemicals with no human RCT data, no Rx path, no manufactured pharmaceutical, COA-dependent gray market only. Selegiline has 40+ years of human data + cheap Rx access. Tradeoff: pick selegiline for evidence + access, BPAP for theoretical-mechanism-purity.

Emsam vs oral — is the patch ever worth it for a healthy young user?

Probably not. The patch's advantages (1) bypass first-pass + lower metabolite load and (2) deliver MAO-A inhibition without gut MAO-A inhibition. For a healthy young user without depression: (1) is irrelevant — at 1-2.5 mg oral the metabolite load is already low + favorable (L-isomers), and (2) is a feature you don't need (you don't WANT MAO-A inhibition for nootropic purposes — that's where the tyramine cliff begins). Patch makes sense for depression, not for a 20yo's brain-preservation use case.

The external source claim "Emsam was the best thing ever, slice of cheese could kill them"

This is real — and important to frame correctly. The person describing this experience was on the 9-12 mg patch tier where Emsam becomes a non-selective MAOI with full tyramine liability. At that tier:

  • The "best thing ever" piece is plausible — non-selective MAOI mood/cognitive effects can be transformative for the right person.
  • The "slice of cheese could kill them" piece is also plausible — hypertensive crisis from aged cheese on 9-12 mg patch is a real ER event.

This experience does NOT apply to the 1-2.5 mg oral tier or the 6 mg patch tier — both of which preserve gut MAO-A barrier and don't have the cheese-cliff. Misreading this story as "selegiline = dangerous, skip" is a category error. Selegiline at the low-oral tier is closer in safety profile to a daily B-vitamin than to a non-selective MAOI.

▸ Verdict change log
  • 2026-05-05 — Initial verdict (encyclopedia entry): low-oral STRONG-CANDIDATE post-baseline; Emsam SKIP as "overkill for nootropic dose"
  • 2026-05-05 — Compound file (this entry): Frontmatter verdict STRONG-CANDIDATE applies to LOW-ORAL TIER. Tier 2 (Emsam 6 mg) downgraded from SKIP to OPTIONAL-ADD/WATCH-LIST after considering possibility Dylan's baseline reveals mood gap. Tier 3 (Emsam 9-12 mg) WATCH-LIST given diet constraint at age 20. Confidence MEDIUM (vs HIGH) reflecting thin direct evidence in healthy young adults.
▸ Open questions / gaps Open
  1. Direct cognitive RCT data in healthy young adults — doesn't exist. Would change verdict to PRIMARY-PICK with HIGH confidence if a well-powered trial showed PFC/working-memory benefit at 1-2.5 mg.
  2. Brain-imaging data in subconcussive impact populations (boxers, MMA, contact sport) — would significantly strengthen case for Dylan-archetype use.
  3. Pharmacogenomic prediction of response — emerging field. Direct CYP2B6 + COMT + DRD2 prospective study would let Dylan personalize after 23andMe results.
  4. BPAP human cognitive trial — would either obviate selegiline (pure CAE without MAO liability) or confirm selegiline's secondary CAE mechanism is independently meaningful.
  5. Long-term (10+ year) safety in chronic low-dose users — most data is in PD patients (older + on levodopa) or short-term healthy. Real-world durability of low-oral safety profile in 20yo→40yo chronic use is undocumented.
▸ Sources (full, with our context)
Back to compact view